

# Intrapartum Fetal Monitoring

James J. Arnold, DO

Eglin Family Medicine Residency, Eglin Air Force Base, Florida

Breanna L. Gawrys, DO

Saint Louis University Family Medicine Residency Program, Scott Air Force Base, Illinois

Continuous electronic fetal monitoring was developed to screen for signs of hypoxic-ischemic encephalopathy, cerebral palsy, and impending fetal death during labor. Because these events have a low prevalence, continuous electronic fetal monitoring has a false-positive rate of 99%. The widespread use of continuous electronic fetal monitoring has increased operative and cesarean delivery rates without improved neonatal outcomes, but its use is appropriate in high-risk labor. Structured intermittent auscultation is an underused form of fetal monitoring; when employed during low-risk labor, it can lower rates of operative and cesarean deliveries with neonatal outcomes similar to those of continuous electronic fetal monitoring. However, structured intermittent auscultation remains difficult to implement because of barriers in nurse staffing and physician oversight. The National Institute of Child Health and Human Development terminology is used when reviewing continuous electronic fetal monitoring and delineates fetal risk by three categories. Category I tracings reflect a lack of fetal acidosis and do not require intervention. Category II tracings are indeterminate, are present in the majority of laboring patients, and can encompass monitoring predictive of clinically normal to rapidly developing acidosis. Presence of moderate fetal heart rate variability and accelerations with absence of recurrent pathologic decelerations provides reassurance that acidosis is not present. Category II tracing abnormalities can be addressed by treating reversible causes and providing intrauterine resuscitation, which includes stopping uterine-stimulating agents, fetal scalp stimulation and/or maternal repositioning, intravenous fluids, or oxygen. Recurrent deep variable decelerations can be corrected with amnioinfusion. Category III tracings are highly concerning for fetal acidosis, and delivery should be expedited if immediate interventions do not improve the tracing. (*Am Fam Physician*. 2020;102(3):158-167. Copyright © 2020 American Academy of Family Physicians.)

**Continuous electronic fetal monitoring** is the continuous monitoring of fluctuations of the fetal heart rate (FHR) in relation to maternal contractions and is considered standard practice during active labor.<sup>1-3</sup> Continuous electronic fetal monitoring was developed for widespread use in the 1970s as a screening test for fetal hypoxia/acidosis during labor, specifically to reduce hypoxic-ischemic encephalopathy, cerebral palsy, and fetal death.<sup>1-3</sup>

Fetal acidemia (pH < 7.15) is most accurately diagnosed via umbilical cord arterial sampling immediately after delivery.<sup>4-6</sup> Because fetal acidosis can affect autonomic control and therefore variability of FHR, continuous electronic fetal monitoring is considered a surrogate marker

for measurement.<sup>2,7</sup> However, the very low prevalence of cerebral palsy (antepartum events are most likely causative agents), hypoxic-ischemic encephalopathy, and fetal death has led to a false-positive rate of 99%<sup>3</sup> for continuous electronic fetal monitoring and a low predictive value.<sup>8-10</sup> Additionally, continuous electronic fetal monitoring is falsely

## BEST PRACTICES IN OBSTETRICS

### Recommendations from the Choosing Wisely Campaign

Recommendation	Sponsoring organization
Do not automatically initiate continuous electronic fetal heart rate monitoring during labor for women without risk factors; consider intermittent auscultation first.	American Academy of Nursing

**Source:** For more information on the Choosing Wisely Campaign, see <https://www.choosingwisely.org>. For supporting citations and to search Choosing Wisely recommendations relevant to primary care, see <https://www.aafp.org/afp/recommendations/search.htm>.

**Additional content** at <https://www.aafp.org/afp/2020/0801/p158.html>.

**CME** This clinical content conforms to AAFP criteria for CME. See CME Quiz on page 143.

**Author disclosure:** No relevant financial affiliations.

**Patient information:** A handout on this topic, written by the authors of this article, is available at <https://www.aafp.org/afp/2020/0801/p158-s1.html>.

positive for fetal acidosis two-thirds of the time, with low sensitivity (57%) and specificity (69%).<sup>1,3</sup> Furthermore, user variability in interpretation is high, with agreement between experts only half the time.<sup>11,12</sup>

Continuous electronic fetal monitoring includes external and internal monitoring.<sup>7</sup> External monitoring involves placement of two monitors (one for FHR and the other for contractions) against the maternal abdomen. Internal monitoring involves intravaginal placement of monitors within the uterine cavity.<sup>7</sup> A fetal scalp electrode is recommended for fetal heart monitoring when fetal position and/or maternal habitus make external monitoring suboptimal.<sup>4</sup> External monitors measure only contraction frequency, but an intrauterine pressure catheter can also determine the strength of contractions.<sup>13</sup> Placement of an intrauterine pressure catheter or fetal scalp electrode requires cervical dilation and amniotomy, which can increase the risk of intrauterine infection, fetal injury, and the transmission of herpes simplex virus and hepatitis B or C.<sup>4,13</sup>

Structured intermittent auscultation is a fetal monitoring option for detecting fetal acidosis in low-risk pregnancies.<sup>7,14,15</sup> Typically, the labor nurse auscultates the fetal heartbeat with a handheld Doppler device (Table 1).<sup>7,14-17</sup> Structured intermittent auscultation is not standard practice in the United States because of 1:1 nursing staff requirements and physician oversight concerns, whereas continuous electronic fetal monitoring can be monitored centrally with continuous recording capabilities.<sup>7,14-18</sup>

Despite these challenges, structured intermittent auscultation should be considered for low-risk labor because it statistically decreases cesarean and operative vaginal delivery rates without an increase in unfavorable outcomes associated with continuous monitor use and a high false-positive rate.<sup>1,7,14,16,17</sup> Compared with women who receive structured intermittent auscultation, those who receive continuous electronic fetal monitoring for an initial 20-minute period at admission are at increased risk of

TABLE 1

### Guidelines for Structured Intermittent Auscultation During Labor

The clinician and the patient with a low-risk pregnancy discuss the benefits of structured intermittent auscultation vs. continuous electronic fetal monitoring; patient agreement to structured intermittent auscultation is documented in medical record; labor team ensures appropriate nurse staffing (1:1)

Labor nurse determines current fetal position and best location to place Doppler handheld probe (usually over the fetal back) with Leopold maneuvers; transabdominal ultrasonography (passive mode) can be used to identify the location of the fetal heart if manual palpation proves difficult

With one hand holding the probe in place, the other hand palpates the uterine fundus to detect maternal contractions

Following contractions, baseline fetal heart rate is assessed by counting the number of beats during a 30- to 60-second interval

For a minimum of 1 minute following contraction onset, fetal heart rate is reassessed at 6- to 10-second intervals to detect accelerations or decelerations in heart rate

#### Recommended frequency of structured intermittent auscultation during labor\*†

Organization	Latent phase	Active phase	Second stage
American College of Nurse-Midwives	No recommendation	15 to 30 minutes	5 minutes
American College of Obstetricians and Gynecologists	No recommendation	30 minutes	15 minutes
Association of Women's Health, Obstetric and Neonatal Nurses	At least hourly (< 4 cm cervical dilation)	15 to 30 minutes (4- to 5-cm cervical dilation)	5 to 15 minutes

\*—All recommended frequencies are expert opinion. No set frequency has been determined to be superior in the current literature.

†—If an irregular rhythm (audible extra and/or dropped beats), fetal tachycardia (> 160 beats per minute for > 10 minutes), fetal bradycardia (< 110 beats per minute for > 10 minutes), or repeat deceleration following contractions occurs, switch to continuous electronic fetal monitoring to assess the National Institute of Child Health and Human Development category and to determine necessary clinical management.

Information from references 7 and 14-17.

continuing use for the duration of their labor (relative risk [RR] = 1.30; 95% CI, 1.14 to 1.48; n = 10,753) and a possible 20% increased rate of cesarean delivery.<sup>19</sup>

Structured intermittent auscultation detects changes in FHR during contractions but not overall FHR variability (moment-by-moment fluctuations in FHR)<sup>4,5</sup>; therefore, continuous electronic fetal monitoring remains the more appropriate option in high-risk labor (Table 2<sup>14,16,17</sup>).

Continuous electronic fetal monitoring, compared with structured intermittent auscultation, has been shown to increase the need for cesarean delivery (number needed to harm = 56; RR = 1.63; 95% CI, 1.29 to 2.07; n = 18,861) and

TABLE 2

### Antepartum and Intrapartum Factors Indicating High-Risk Labor and the Need for Continuous Electronic Fetal Monitoring\*

#### Antepartum

Any condition in which placental insufficiency is suspected  
 Known fetal anomalies  
 Maternal preeclampsia/gestational hypertension  
 Maternal type 1 diabetes mellitus  
 Suspected fetal growth restriction

#### Intrapartum

Presence of meconium  
 Presence of tachysystole  
 Signs/symptoms of intrauterine infection  
 Unexplained vaginal bleeding  
 Use of oxytocin (Pitocin) or other uterine stimulants for labor induction or augmentation

If one of the following is detected during structured intermittent auscultation for a low-risk patient, switch to continuous electronic fetal monitoring to assess the National Institute of Child Health and Human Development category and to determine necessary clinical management:

- Irregular fetal heart rate
- Fetal tachycardia (> 160 beats per minute for > 10 minutes)
- Fetal bradycardia (< 110 beats per minute for > 10 minutes)
- Recurrent decelerations following contractions (> 50% of contractions) or prolonged deceleration (> 2 minutes but < 10 minutes)

\*—Likely not a complete list, but what is considered high risk by the American College of Obstetricians and Gynecologists, International Federation of Gynecology and Obstetrics, and American College of Nurse-Midwives by expert opinion in their major practice guidelines.

Information from references 14, 16, and 17.

TABLE 3

### National Institute of Child Health and Human Development Categories for Continuous Electronic Fetal Monitoring

Category I (normal)	Must be present: Baseline fetal heart rate of 110 to 160 beats per minute Moderate variability Absent late or variable decelerations May be present or absent: Accelerations Early decelerations
Category II (indeterminate)	Any tracing not meeting the criteria of Category I or III, with any of the following findings: Fetal tachycardia Baseline fetal heart rate with absent/minimal/moderate variability Recurrent late decelerations with moderate variability Variable decelerations with slow return to (or overshoots) baseline Prolonged decelerations No accelerations after fetal scalp stimulation
Category III (pathologic)	Must be present: Sinusoidal pattern Absent fetal heart rate variability with recurrent late decelerations, recurrent variable decelerations, or fetal bradycardia

Information from references 4, 5, and 7.

operative vaginal delivery (number needed to harm = 41; RR = 1.15; 95% CI, 1.01 to 1.33; n = 18,615), with no statistical decrease in fetal death or cerebral palsy.<sup>1</sup> Continuous electronic fetal monitoring has also led to a 50% reduction in the incidence of neonatal seizure vs. structured intermittent auscultation, but this has no effect on long-term outcomes.<sup>1</sup>

### Continuous Electronic Fetal Monitoring Adjuncts

Several adjuncts have been studied to overcome the high false-positive rate of continuous electronic fetal monitoring. Fetal scalp sampling, which requires amniotomy, tests fetal pH for the presence of acidemia.<sup>16</sup> However, because of a 10% inadequate sample rate and a prolonged sample-to-result time of 18 minutes on average, this test is rarely performed in the United States.<sup>20</sup> Lactate fetal scalp sampling (direct measurement of lactate by a probe) is another option that boasts a sample-to-result time of two minutes; however, its use has not resulted in improved newborn outcomes.<sup>21</sup> An

internal real-time fetal pulse oximetry probe (similar to an intrauterine pressure catheter) may lower operative vaginal delivery rates during the second stage of labor but has no apparent effect on neonatal outcomes.<sup>22,23</sup> Fetal electrocardiograms have also been studied because fetal acidosis can affect the ST interval. These require attachment of fetal head electrodes; a recent randomized controlled trial and meta-analysis showed no improvement in neonatal outcomes or rates of operative or cesarean delivery.<sup>24,25</sup>

### Fetal Monitoring Classifications

The National Institute of Child Health and Human Development terminology (revised in 2008) classifies continuous electronic fetal monitoring tracings using a three-tiered system and is the accepted national standard for continuous electronic fetal monitoring interpretation.<sup>5</sup> Labor management depends on the continuous electronic fetal monitoring category and overall clinical scenario (*Table 3*).<sup>4,5,7</sup>

Interpretation of continuous electronic fetal monitoring tracings must include comments on uterine contractions, baseline FHR, variability (fluctuations in the FHR around

TABLE 4

### DR C BRAVADO: Mnemonic for Standardizing Tracing Interpretation and Reporting Tool for Fetal Heart Rate Monitoring

DR	Determine risk*	Normal	Suspicious†	Pathologic
C	Contractions	≤ 5 contractions in 10-minute period averaged over 30 minutes	Tachysystole: > 5 contractions in 10-minute period averaged over 30 minutes	No response to intrauterine resuscitative measures; stopping/reducing uterotonic agents or tocolytics with persistent Category II/III tracing
BRa	Baseline rate	110 to 160 bpm; determine by 2-minute segment in 10-minute period	< 110 bpm: bradycardia > 160 bpm: tachycardia Rate change that persists for > 2 minutes means baseline has changed	< 100 bpm
V	Variability	Fluctuations from baseline over 10-minute period, with 6 to 25 bpm: moderate	≤ 5: minimal ≥ 25: marked	Absent variability Sinusoidal pattern: fetal heart rate baseline undulating every 3 to 5 minutes for ≥ 20 minutes
A	Accelerations	≥ 15 bpm above baseline rate, onset to peak < 30 seconds, lasts for at least 15 seconds‡ Prolonged: ≥ 2 minutes Baseline change: ≥ 10 minutes	None present	None present despite scalp stimulation
D	Decelerations	Early: onset to nadir ≥ 30 seconds, nadir occurs with peak of contraction Due to fetal head compression	Variable: onset to nadir < 30 seconds, decrease in fetal heart rate ≥ 15 bpm with duration ≥ 15 seconds to < 2 minutes Due to cord compression Late: onset to nadir ≥ 30 seconds, onset after start of contraction Recurrent: occurs with > 50% of contractions per 20-minute period Prolonged: > 2 minutes Due to uteroplacental insufficiency	Recurrent late or prolonged decelerations for > 30 minutes or for > 20 minutes if reduced variability Prolonged decelerations > 5 minutes
O	Overall assessment	No hypoxia/acidosis; no intervention necessary	Low probability of hypoxia/acidosis; take action to correct reversible causes and monitor closely	High probability of hypoxia/acidosis; take immediate action to correct reversible causes and expedite delivery

bpm = beats per minute.

\*—Based on prenatal and intrapartum risk factors, fetal reserve, labor progress, and risk of uteroplacental insufficiency.

†—Lacking at least one characteristic of normal but no pathologic features. Suspicious features include slow return to baseline, biphasic decelerations, and tachycardia after variable decelerations or accelerations preceding and/or following ("overshoots").

‡—For estimated gestational age ≥ 32 weeks; for estimated gestational age < 32 weeks, accelerations 10 bpm above baseline lasting for > 10 seconds.

Information from references 4, 5, 7, 14, 16, and 26.

the determined baseline during a 10-minute segment), presence of accelerations and/or decelerations, and trends of continuous electronic fetal monitoring patterns over time.<sup>2,5</sup>

DR C BRAVADO (determine risk, contractions, baseline rate, variability, accelerations, decelerations, overall assessment) is a mnemonic that serves as a standardized tracing interpretation and reporting tool<sup>14</sup> (Table 4<sup>4,5,7,14,16,26</sup>).

#### Tachysystole Identification and Management


Uterine tachysystole is defined as more than five contractions in any 10-minute period, averaged over 30 minutes.<sup>2</sup> Each

normal uterine contraction causes a temporary decrease in uterine blood flow and fetal oxygenation, which is generally well tolerated.<sup>26,27</sup> However, tachysystole increases the risk of acidosis.<sup>26,27</sup> To correct tachysystole, physicians must reduce or stop uterine stimulants or add tocolytics.<sup>2,27-29</sup>

#### Intrapartum Fetal Monitoring: Identification and Management

Goals of intrapartum fetal monitoring include rapid identification and intervention for suspected fetal acidosis as well as reassurance and avoidance of unnecessary interventions

FIGURE 1



\*—Intrauterine resuscitation and interventions

1. Change maternal position (lateral recumbent, hands/knees)
2. Assess maternal vital signs (hypotension, fever, tachycardia) and correct as able
3. Discontinue uterine stimulation (stop oxytocin [Pitocin] if using, remove dinoprostone [Cervidil] if in place)
4. Consider use of tocolytics such as terbutaline
5. Administer maternal oxygen via nonrebreather at 10 L per minute
6. Perform vaginal examination (assess for placental abruption, cord prolapse, rapid descent)
7. Bolus 1 L intravenous fluid
8. Initiate amnioinfusion if repetitive variable decelerations present
9. Modify pushing efforts if in second stage of labor
10. Consider need for expedited delivery

†—Clarifications for Category II management

Significant decelerations:

- Variable decelerations > 60 seconds and with nadir > 60 beats per minute below baseline or < 60 beats per minute

Late decelerations

- Initiation of algorithm may be delayed 30 minutes while assessing whether intrauterine resuscitation methods worked
- If expedited delivery is recommended, accomplish within 30 minutes
- Algorithm may be overridden at any time if it is determined to be in the best interest of the fetus to act earlier

‡—Normal labor progress in active phase: ≥ 6-cm dilation with ruptured membranes and increase of cervical dilation/effacement/fetal station with either 4 hours of adequate cervical contractions (200 mVUs) or 6 hours of inadequate contractions

§—Normal labor progress in second phase: advancement in fetal station after 2 hours of pushing in multiparous women or 3 hours in nulliparous women without an epidural; 3 hours in multiparous women or 4 hours in nulliparous women with an epidural

**Algorithm to determine the National Institute of Child Health and Human Development category of continuous electronic fetal monitoring.**

Information from references 2, 7, 16, 21, 27, and 30-33.


in cases of adequate fetal oxygenation.<sup>4,26</sup> Figure 1 provides an algorithm for suggested management.<sup>2,7,16,21,27,30-33</sup>

**CATEGORY I MANAGEMENT**

Category I is defined by an FHR baseline of 110 to 160 beats per minute (bpm), moderate variability (six- to 25-bpm fluctuation in FHR from baseline), with no late decelerations

(onset and nadir after peak of contraction, decrease of more than 15 bpm from baseline, likely uteroplacental insufficiency) and no variable decelerations (onset variable to contraction and slow [i.e., more than 15 seconds and less than two minutes] return to baseline, likely from cord compression) present<sup>3</sup> (Figure 27). Early decelerations (mirror contraction, with nadir at peak of contraction, likely fetal

FIGURE 2



### Category I tracing with fetal heart rate accelerations.

Reprinted with permission from Leeman L, Quinlan JD, Dresang LT, et al.; American Academy of Family Physicians. Advanced Life Support in Obstetrics: provider manual; 2017. Accessed January 17, 2020. <https://nf.aafp.org/Shop/product/DetailByName?categoryName=advanced-life-support-in-obstetrics&productName=also-provider-manual-print>

head compression) and accelerations (FHR increase of 15 bpm or more over at least 15 seconds) may be present.<sup>2,5,7,34</sup> No intervention is required for Category I tracings.

## CATEGORY II MANAGEMENT

Category II tracings are defined as indeterminate, are common, and represent all tracings that do not fall into the Category I or III groups.<sup>2,5</sup> They vary widely in level of concern for acidosis, so the family physician must determine the severity of the Category II tracing and take the appropriate action.<sup>2,5,7,35</sup>

There is a direct association between fetal acidosis, recurrent decelerations, and depth of decelerations<sup>2,5,34,36</sup>; however, the presence of moderate variability and/or accelerations offers reassurance in Category II tracings because the presence is predictive of a lack of fetal acidosis.<sup>2,4,26,27,34,36-38</sup> For Category II tracings without spontaneous or provoked accelerations, minimal/absent variability, or deep decelerations (i.e., FHR drops to 70 bpm or less), immediate action is needed.<sup>3,4</sup>

A management algorithm<sup>30</sup> (eFigure A) has been developed that is based on the suspected degree of fetal acidosis and ideally minimizes unnecessary interventions.<sup>7</sup>

A five-tiered classification/management scheme for management of Category II tracings has been developed (<http://www.obapps.org>).<sup>7,37,39</sup> Each continuous electronic fetal monitoring tracing is color coded to represent the threat of acidosis based on the National Institute of Child Health and Human Development definitions, and Category II is broken

into three separate severity and intervention subcategories based on the presence of accelerations and/or moderate variability.<sup>7,37</sup> This classification has been shown to improve identification of fetal acidosis and newborns requiring immediate intervention after delivery.<sup>37</sup>

Category II management should focus on first correcting reversible causes, including stopping uterotonic agents and placental fetal perfusion, through intrauterine resuscitation (Figure 1).<sup>2,7,16,21,27,30-33</sup> Lateral recumbent maternal positioning reduces compression of the maternal vena cava and aorta and the fetal umbilical cord.<sup>2,32,33</sup> Intravenous fluid boluses up to 1 L have been shown to improve fetal oxygenation up to 30 minutes after administration.<sup>32,33</sup> Maternal oxygen may be administered after other maneuvers, but it can be discontinued after tracing improvement because there is no evidence to support its routine use.<sup>2,32,33</sup> Modification in maternal pushing efforts, such as initiating only with the urge to push and allowing for fetal recovery by pushing with every second or third contraction, can improve maternal and fetal oxygenation.<sup>40</sup>

## CATEGORY III MANAGEMENT

Category III tracings, defined by a sinusoidal FHR pattern (Figure 3<sup>7</sup>) or absent FHR variability (Figure 4<sup>7</sup>) with recurrent late and/or variable decelerations or fetal bradycardia (see the Fetal Bradycardia section), require immediate intrauterine resuscitation and intervention.<sup>2,5,8,14,27,30,32,33,38,39</sup> If the Category III tracing does not rapidly improve, expedited delivery is recommended. Category III tracings have been associated with fetal hypoxia, acidosis, and encephalopathy.<sup>2,5,26,37</sup>

## Specific Tracing Findings and Management

### FETAL TACHYCARDIA

Fetal tachycardia (FHR of more than 160 bpm for at least 10 minutes) can be caused by maternal or fetal factors (Table 5<sup>2,5,7</sup> and eFigure B). Management includes correction of identified reversible causes. This alone is not predictive of fetal acidosis unless accompanied by decreased variability and/or absent spontaneous or stimulated accelerations.<sup>2,5</sup>


### FETAL BRADYCARDIA

Fetal bradycardia (FHR less than 110 bpm for at least 10 minutes) is more concerning than fetal tachycardia, and interventions should focus on intrauterine resuscitation and treating reversible maternal or fetal causes (Table 6<sup>2,5,7</sup> and eFigure C).

### MINIMAL FHR VARIABILITY

Decreased variability is defined as a variation of one to five bpm from baseline for at least 10 minutes<sup>5</sup> (eFigure D).


**FIGURE 3**



**Sinusoidal fetal heart rate pattern.**

Reprinted with permission from Leeman L, Quinlan JD, Dresang LT, et al.; American Academy of Family Physicians. Advanced Life Support in Obstetrics: provider manual; 2017. Accessed January 17, 2020. <https://nf.aafp.org/Shop/product/DetailByName?categoryName=advanced-life-support-in-obstetrics&productName=also-provider-manual-print>

**FIGURE 4**



**Absent fetal heart rate variability.**

Reprinted with permission from Leeman L, Quinlan JD, Dresang LT, et al.; American Academy of Family Physicians. Advanced Life Support in Obstetrics: provider manual; 2017. Accessed January 17, 2020. <https://nf.aafp.org/Shop/product/DetailByName?categoryName=advanced-life-support-in-obstetrics&productName=also-provider-manual-print>

**TABLE 5**

**Causes of Fetal Tachycardia**

Maternal	Fetal
Anemia	Anemia
Anxiety	Cardiac anomalies
Dehydration	Chronic hypoxia
Fever/infection	Prolonged activity
Stimulants	Severe prematurity

Information from references 2, 5, and 7.

Minimal variability during the hour preceding fetal bradycardic events has been shown to be most predictive of fetal acidosis and need for emergent delivery.<sup>23</sup> During periods of minimal variability, accelerations produced by scalp stimulation offer reassurance.<sup>15,23,26,41</sup> Management of minimal variability includes intrauterine resuscitation and identifying and treating reversible causes (Table 7).<sup>2,7,16</sup>

**MARKED FHR VARIABILITY**

Marked variability is defined as more than 25 bpm fluctuations in FHR around the determined baseline for more than 10 minutes and may represent hypoxic stress<sup>5,33</sup> (eFigure E). Management includes further investigation into and correction of possible stressors.<sup>14,33</sup>

**RECURRENT VARIABLE DECELERATIONS**

Variable decelerations are recurrent when they occur with greater than 50% of contractions in any 20-minute period<sup>2,5</sup>

**TABLE 6**

**Causes of Fetal Bradycardia**

Maternal	Fetal
Excessive vagal stimulation	Cardiac defects
Hypoglycemia	Cord compression
Hypotension	Hypoxia
Hypothermia	Postterm > 42 weeks

Information from references 2, 5, and 7.

**TABLE 7**

**Causes of Decreased Fetal Heart Rate Variability**

- Cocaine use
- Corticosteroids\*
- Fetal sleep cycles (20 to 40 minutes)
- General anesthesia
- Hypoxia/acidosis†
- Maternal fever
- Medications: magnesium sulfate,† opioids,‡ benzodiazepines, anticholinergics


\*—Decrease in fetal heart rate variability with betamethasone but not dexamethasone.

†—Decrease in short-term variability, clinically insignificant decrease in fetal heart rate, and decreased accelerations.

‡—Also can cause decreased accelerations.

Information from references 2, 7, and 16.


FIGURE 5



Variable fetal heart rate decelerations.

Reprinted with permission from Leeman L, Quinlan JD, Dresang LT, et al.; American Academy of Family Physicians. Advanced Life Support in Obstetrics: provider manual; 2017. Accessed January 17, 2020. <https://nf.aafp.org/Shop/product/DetailByName?categoryName=advanced-life-support-in-obstetrics&productName=also-provider-manual-print>


FIGURE 6



Late fetal heart rate decelerations.

Reprinted with permission from Leeman L, Quinlan JD, Dresang LT, et al.; American Academy of Family Physicians. Advanced Life Support in Obstetrics: provider manual; 2017. Accessed January 17, 2020. <https://nf.aafp.org/Shop/product/DetailByName?categoryName=advanced-life-support-in-obstetrics&productName=also-provider-manual-print>

FIGURE 7



Prolonged fetal heart rate decelerations.

Reprinted with permission from Leeman L, Quinlan JD, Dresang LT, et al.; American Academy of Family Physicians. Advanced Life Support in Obstetrics: provider manual; 2017. Accessed January 17, 2020. <https://nf.aafp.org/Shop/product/DetailByName?categoryName=advanced-life-support-in-obstetrics&productName=also-provider-manual-print>

LATE DECELERATIONS

Management of late decelerations includes intrauterine resuscitation and identifying and treating reversible causes, with immediate delivery recommended if they do not resolve<sup>2,5,7</sup> (Figure 6<sup>7</sup>).

PROLONGED DECELERATIONS

Prolonged FHR decelerations from baseline (more than two minutes but less than 10 minutes) may represent rapid cervical change and/or fetal descent, maternal hypotension, placental abruption, umbilical cord prolapse, or uterine rupture<sup>2,5,26</sup> (Figure 7<sup>7</sup>). If decelerations are not reversed by intrauterine resuscitation measures, immediate delivery is recommended.<sup>2,43</sup>

This article updates previous articles on this topic by Bailey<sup>44</sup> and by Sweha, et al.<sup>45</sup>

**Data Sources:** PubMed searches were completed using the key terms intrapartum fetal heart monitoring, cardiotocography, structured fetal heart monitoring, National Institute of Child Health and Human Development classifications, amnioinfusion, and advanced life support in obstetrics. The searches included systematic reviews, meta-analyses, randomized controlled trials, and review articles. We also searched the Cochrane Library, Essential Evidence Plus, and Clinical Evidence. Search dates: December 2018, July 2019, and March 2020.

**The views** expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Air Force, Uniformed Services University of the Health Sciences, Department of Defense, or the U.S. government.

(Figure 5<sup>7</sup>). Recurrent variable decelerations can be treated with amnioinfusion, the placement of isotonic fluids into the intrauterine cavity, with the same requirement and risks as the intrauterine pressure catheter and fetal scalp electrode mentioned previously.<sup>7</sup> Amnioinfusion has been shown to reduce cord compression, leading to resolution of FHR decelerations (RR = 0.53; 95% CI, 0.38 to 0.74; n = 1,000) and lowering the likelihood of cesarean delivery (RR = 0.62; 95% CI, 0.46 to 0.83; n = 1,400).<sup>26,42</sup>



## SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation	Evidence rating	Comments
Structured intermittent auscultation can be used for low-risk labor because it statistically decreases cesarean and operative vaginal delivery rates without increasing cerebral palsy or fetal death. <sup>1,14,16</sup>	<b>B</b>	Cochrane review of low-quality evidence and practice guidelines from the American College of Obstetricians and Gynecologists
The presence of moderate variability and/or accelerations is predictive of a lack of fetal acidosis. <sup>34,36-38</sup>	<b>C</b>	Reviews of disease-oriented outcomes
Treat placental fetal perfusion through intrauterine resuscitation before proceeding to immediate delivery for all Category II or III tracings with concern for fetal acidosis. <sup>27,32,33</sup>	<b>C</b>	Guidelines, with one small disease-oriented randomized controlled trial and one Cochrane review focusing on tocolytics aspect of intrauterine resuscitation
Perform amnioinfusion for recurrent variable decelerations to reduce the risk of cesarean delivery. <sup>42</sup>	<b>B</b>	Cochrane review of low-quality evidence

**A** = consistent, good-quality patient-oriented evidence; **B** = inconsistent or limited-quality patient-oriented evidence; **C** = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <https://www.aafp.org/afpsort>.

## The Authors

**JAMES J. ARNOLD, DO, FACOFP, FAAFP**, is the Director of Osteopathic Education and family medicine obstetric faculty of the Eglin Family Medicine Residency, Eglin Air Force Base, Fla., and an associate professor in the Department of Family Medicine at the Uniformed Services University of the Health Sciences, Bethesda, Md.

**BREANNA L. GAWRYS, DO**, is family medicine obstetric faculty of the Saint Louis University Family Medicine Residency Program, Scott Air Force Base, Ill.; an assistant professor in the Department of Family Medicine at the Saint Louis School of Medicine, O'Fallon, Ill.; a faculty physician at the Health Sisters Hospital System, O'Fallon; and an assistant professor in the Department of Family Medicine at the Uniformed Services University of the Health Sciences.

Address correspondence to James J. Arnold, DO, FACOFP, FAAFP, 307 Boatner Rd., Eglin AFB, FL 32542 (email: james.j.arnold42.mil@mail.mil). Reprints are not available from the authors.


## References

- Alfirevic Z, Gyte GM, Cuthbert A, et al. Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. *Cochrane Database Syst Rev*. 2017;(2):CD006066.
- American College of Obstetricians and Gynecologists. Practice bulletin no. 116: management of intrapartum fetal heart rate tracings. *Obstet Gynecol*. 2010;116(5):1232-1240.
- Grimes DA, Peipert JF. Electronic fetal monitoring as a public health screening program: the arithmetic of failure. *Obstet Gynecol*. 2010;116(6):1397-1400.
- Ayres-de-Campos D, Spong CY, Chandrachan E; FIGO Intrapartum Fetal Monitoring Expert Consensus Panel. FIGO consensus guidelines on intrapartum fetal monitoring: cardiotocography. *Int J Gynaecol Obstet*. 2015;131(1):13-24.
- Macones GA, Hankins GD, Spong CY, et al. The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. *Obstet Gynecol*. 2008;112(3):661-666.
- Duerbeck NB, Chaffin DG, Seeds JW. A practical approach to umbilical artery pH and blood gas determinations. *Obstet Gynecol*. 1992;79(6):959-962.
- Leeman L, Quinlan JD, Dresang LT, et al.; American Academy of Family Physicians. Advanced Life Support in Obstetrics: provider manual; 2017. Accessed January 17, 2020. <https://nf.aafp.org/Shop/product/DetailByName?categoryName=advanced-life-support-in-obstetrics&productName=also-provider-manual-print>
- Larma JD, Silva AM, Holcroft CJ, et al. Intrapartum electronic fetal heart rate monitoring and the identification of metabolic acidosis and hypoxic-ischemic encephalopathy. *Am J Obstet Gynecol*. 2007;197(3):301.e1-301.e8.
- Graham EM, Petersen SM, Christo DK, et al. Intrapartum electronic fetal heart rate monitoring and the prevention of perinatal brain injury. *Obstet Gynecol*. 2006;108(3 pt 1):656-666.
- Nelson KB, Dambrosia JM, Ting TY, et al. Uncertain value of electronic fetal monitoring in predicting cerebral palsy. *N Engl J Med*. 1996;334(10):613-618.
- Chauhan SP, Klausner CK, Woodring TC, et al. Intrapartum nonreassuring fetal heart rate tracing and prediction of adverse outcomes: interobserver variability. *Am J Obstet Gynecol*. 2008;199(6):623.e1-623.e5.
- Vayssière C, Tsatsaris V, Pirrello O, et al. Inter-observer agreement in clinical decision-making for abnormal cardiotocogram (CTG) during labour: a comparison between CTG and CTG plus STAN. *BJOG*. 2009;116(8):1081-1087, discussion 1087-1088.
- Bakker JJ, Janssen PF, van Halem K, et al. Internal versus external tocodynamometry during induced or augmented labour. *Cochrane Database Syst Rev*. 2013;(8):CD006947.
- Lewis D, Downe S; FIGO Intrapartum Fetal Monitoring Expert Consensus Panel. FIGO consensus guidelines on intrapartum fetal monitoring: intermittent auscultation. *Int J Gynaecol Obstet*. 2015;131(1):9-12.
- Association of Women's Health, Obstetric, and Neonatal Nurses. Position statement: fetal heart monitoring. *J Obstet Gynecol Neonatal Nurs*. 2015;44(5):683-686.

## INTRAPARTUM FETAL MONITORING

16. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 106: intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. *Obstet Gynecol*. 2009;114(1):192-202.
17. American College of Nurse-Midwives. Intermittent auscultation for intrapartum fetal heart rate surveillance [published correction appears in *J Midwifery Womens Health*. 2016;61(1):134]. *J Midwifery Womens Health*. 2015;60(5):626-632.
18. Heelan L. Fetal monitoring: creating a culture of safety with informed choice. *J Perinat Educ*. 2013;22(3):156-165.
19. Devane D, Lalor JG, Daly S, et al. Cardiotocography versus intermittent auscultation of fetal heart on admission to labour ward for assessment of fetal wellbeing. *Cochrane Database Syst Rev*. 2017;(1):CD005122.
20. Visser GH, Ayres-de-Campos D; FIGO Intrapartum Fetal Monitoring Expert Consensus Panel. FIGO consensus guidelines on intrapartum fetal monitoring: adjunctive technologies. *Int J Gynaecol Obstet*. 2015;131(1):25-29.
21. East CE, Leader LR, Sheehan P, et al. Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace. *Cochrane Database Syst Rev*. 2015;(5):CD006174.
22. East CE, Brennecke SP, King JF, et al.; FOREMOST Study Group. The effect of intrapartum fetal pulse oximetry, in the presence of a nonreassuring fetal heart rate pattern, on operative delivery rates: a multicenter, randomized, controlled trial (the FOREMOST trial). *Am J Obstet Gynecol*. 2006;194(3):606.e1-606.e16.
23. Kühnert M, Schmidt S. Intrapartum management of nonreassuring fetal heart rate patterns: a randomized controlled trial of fetal pulse oximetry. *Am J Obstet Gynecol*. 2004;191(6):1989-1995.
24. Belfort MA, Saade GR, Thom E, et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A randomized trial of intrapartum fetal ECG ST-segment analysis. *N Engl J Med*. 2015;373(7):632-641.
25. Neilson JP. Fetal electrocardiogram (ECG) for fetal monitoring during labour. *Cochrane Database Syst Rev*. 2015;(12):CD000116.
26. American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric care consensus no. 1: safe prevention of the primary cesarean delivery. *Obstet Gynecol*. 2014;123(3):693-711.
27. Kulier R, Hofmeyr GJ. Tocolytics for suspected intrapartum fetal distress. *Cochrane Database Syst Rev*. 2000;(2):CD000035.
28. Heuser CC, Knight S, Esplin MS, et al. Tachysystole in term labor: incidence, risk factors, outcomes, and effect on fetal heart tracings [published correction appears in *Am J Obstet Gynecol*. 2014;210(2):162]. *Am J Obstet Gynecol*. 2013;209(1):32.e1-32.e6.
29. Simpson KR, James DC. Effects of oxytocin-induced uterine hyperstimulation during labor on fetal oxygen status and fetal heart rate patterns. *Am J Obstet Gynecol*. 2008;199(1):34.e1-34.e5.
30. Clark SL, Nageotte MP, Garite TJ, et al. Intrapartum management of category II fetal heart rate tracings: towards standardization of care. *Am J Obstet Gynecol*. 2013;209(2):89-97.
31. CTG classification: 2015 revised FIGO guidelines on intrapartum fetal monitoring. Accessed May 6, 2019 <https://www.figo.org/sites/default/files/uploads/wg-publications/CTG%20classification.pdf>
32. Simpson KR, James DC. Efficacy of intrauterine resuscitation techniques in improving fetal oxygen status during labor. *Obstet Gynecol*. 2005;105(6):1362-1368.
33. Simpson KR. Intrauterine resuscitation during labor: review of current methods and supportive evidence. *J Midwifery Womens Health*. 2007;52(3):229-237.
34. Tejani N, Mann LI, Bhakthavathsalan A, et al. Correlation of fetal heart rate-uterine contraction patterns with fetal scalp blood pH. *Obstet Gynecol*. 1975;46(4):392-396.
35. Jackson M, Holmgren CM, Esplin MS, et al. Frequency of fetal heart rate categories and short-term neonatal outcome. *Obstet Gynecol*. 2011;118(4):803-808.
36. Krebs HB, Petres RE, Dunn LJ, et al. Intrapartum fetal heart rate monitoring. VI. Prognostic significance of accelerations. *Am J Obstet Gynecol*. 1982;142(3):297-305.
37. Parer JT, Ikeda T. A framework for standardized management of intrapartum fetal heart rate patterns. *Am J Obstet Gynecol*. 2007;197(1):26.e1-26.e6.
38. Williams KP, Galerneau F. Intrapartum fetal heart rate patterns in the prediction of neonatal acidemia. *Am J Obstet Gynecol*. 2003;188(3):820-823.
39. FHR 5-tier. 2012. Accessed May 6, 2019. <http://www.obapps.org/>
40. Simpson KR, James DC. Effects of immediate versus delayed pushing during second-stage labor on fetal well-being: a randomized clinical trial. *Nurs Res*. 2005;54(3):149-157.
41. Skupski DW, Rosenberg CR, Eglinton GS. Intrapartum fetal stimulation tests: a meta-analysis. *Obstet Gynecol*. 2002;99(1):129-134.
42. Hofmeyr GJ, Lawrie TA. Amnioinfusion for potential or suspected umbilical cord compression in labour. *Cochrane Database Syst Rev*. 2012;(1):CD000013.
43. Young BK, Katz M, Klein SA, et al. Fetal blood and tissue pH with moderate bradycardia. *Am J Obstet Gynecol*. 1979;135(1):45-47.
44. Bailey RE. Intrapartum fetal monitoring. *Am Fam Physician*. 2009;80(12):1388-1396. Accessed January 13, 2020. <https://www.aafp.org/aafp/2009/1215/p1388.html>
45. Sweha A, Hacker TW, Nuovo J. Interpretation of the electronic fetal heart rate during labor. *Am Fam Physician*. 1999;59(9):2487-2500. Accessed January 13, 2020. <https://www.aafp.org/aafp/1999/0501/p2487.html>

eFIGURE A




\*—That have not resolved with appropriate conservative corrective measures, including supplemental oxygen, maternal position changes, intravenous fluid administration, correction of hypotension, reduction or discontinuation of uterine stimulation, administration of uterine relaxant, amnioinfusion, and/or changes in second stage breathing and pushing techniques.

**Management of Category II fetal heart rate tracings.**

Adapted with permission from Clark SL, Nageotte MP, Garite TJ, et al. Intrapartum management of category II fetal heart rate tracings: towards standardization of care. Am J Obstet Gynecol. 2013;209(2):90.

# INTRAPARTUM FETAL MONITORING


**eFIGURE B**



**Fetal tachycardia.**

Reprinted with permission from Leeman L, Quinlan JD, Dresang LT, et al.; American Academy of Family Physicians. Advanced Life Support in Obstetrics: provider manual; 2017. Accessed January 17, 2020. <https://nf.aafp.org/Shop/product/DetailByName?categoryName=advanced-life-support-in-obstetrics&productName=also-provider-manual-print>


**eFIGURE D**



**Minimal fetal heart rate variability.**

Reprinted with permission from Leeman L, Quinlan JD, Dresang LT, et al.; American Academy of Family Physicians. Advanced Life Support in Obstetrics: provider manual; 2017. Accessed January 17, 2020. <https://nf.aafp.org/Shop/product/DetailByName?categoryName=advanced-life-support-in-obstetrics&productName=also-provider-manual-print>


**eFIGURE C**



**Fetal bradycardia.**

Reprinted with permission from Leeman L, Quinlan JD, Dresang LT, et al.; American Academy of Family Physicians. Advanced Life Support in Obstetrics: provider manual; 2017. Accessed January 17, 2020. <https://nf.aafp.org/Shop/product/DetailByName?categoryName=advanced-life-support-in-obstetrics&productName=also-provider-manual-print>

**eFIGURE E**



**Marked fetal heart rate variability.**

Reprinted with permission from Leeman L, Quinlan JD, Dresang LT, et al.; American Academy of Family Physicians. Advanced Life Support in Obstetrics: provider manual; 2017. Accessed January 17, 2020. <https://nf.aafp.org/Shop/product/DetailByName?categoryName=advanced-life-support-in-obstetrics&productName=also-provider-manual-print>